Literature DB >> 1576055

Metabolism of 2',3'-dideoxyinosine (ddI) in human blood.

D J Back1, S Ormesher, J F Tjia, R Macleod.   

Abstract

1. 2',3'-Dideoxyinosine (ddI) has potent activity against human immunodeficiency virus (HIV). It is converted within target cells to its active form dideoxyadenosine triphosphate(ddA-TP). 2. In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase. Since PNP is present in red blood cells we have examined the metabolism of [14C]-ddI by human blood. 3. When incubated with whole blood at 37 degrees C, ddI was extensively metabolised, principally to hypoxanthine (50.4 +/- 12.5% formed at 6 h; mean +/- s.d.; n = 16). Small amounts of uric acid were formed (3.8 +/- 2.4%). 4. ddI breakdown was temperature dependent, being virtually negligible at 4 degrees C. Metabolism to hypoxanthine occurred within red blood cells. 5. The short half-life of ddI in patients is probably the result of both hepatic and erythrocytic metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576055      PMCID: PMC1381283          DOI: 10.1111/j.1365-2125.1992.tb04043.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Purine nucleoside phosphorylase from human erythrocytes.

Authors:  J D Stoeckler; R P Agarwal; K C Agarwal; R E Parks
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

2.  Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; G Ahluwalia; H Mitsuya; A Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

3.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

4.  High-performance liquid chromatographic method for analysis of 2',3'-dideoxyinosine in human body fluids.

Authors:  M E Carpen; D G Poplack; P A Pizzo; F M Balis
Journal:  J Chromatogr       Date:  1990-03-16

5.  Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species.

Authors:  K C Agarwal; R P Agarwal; J D Stoeckler; R E Parks
Journal:  Biochemistry       Date:  1975-01-14       Impact factor: 3.162

6.  Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

Authors:  G Ahluwalia; D A Cooney; H Mitsuya; A Fridland; K P Flora; Z Hao; M Dalal; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

7.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

Authors:  J S Lambert; M Seidlin; R C Reichman; C S Plank; M Laverty; G D Morse; C Knupp; C McLaren; C Pettinelli; F T Valentine
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

9.  Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.

Authors:  M A Johnson; G Ahluwalia; M C Connelly; D A Cooney; S Broder; D G Johns; A Fridland
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

10.  Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism.

Authors:  H A Simmonds; L D Fairbanks; G S Morris; D R Webster; E H Harley
Journal:  Clin Chim Acta       Date:  1988-02-15       Impact factor: 3.786

View more
  12 in total

1.  Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.

Authors:  J M Adams; M J Shelton; R G Hewitt; T H Grasela; M DeRemer; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.

Authors:  D Singhal; M E Morgan; B D Anderson
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

3.  8-Aminoguanosine Exerts Diuretic, Natriuretic, and Glucosuric Activity via Conversion to 8-Aminoguanine, Yet Has Direct Antikaliuretic Effects.

Authors:  Edwin K Jackson; Zaichuan Mi
Journal:  J Pharmacol Exp Ther       Date:  2017-09-19       Impact factor: 4.030

4.  Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.

Authors:  Lucie Durand-Gasselin; David Da Silva; Henri Benech; Alain Pruvost; Jacques Grassi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

5.  Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides?

Authors:  M D Johnson; B D Anderson
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

Review 6.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 7.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

8.  Transfer of dideoxyinosine across the human isolated placenta.

Authors:  G I Henderson; A B Perez; Y Yang; R L Hamby; R S Schenken; S Schenker
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

9.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.

Authors:  Déborah Hirt; Christophe Bardin; Serge Diagbouga; Boubacar Nacro; Hervé Hien; Emmanuelle Zoure; François Rouet; Adama Ouiminga; Saik Urien; Vincent Foulongne; Philippe Van De Perre; Jean-Marc Tréluyer; Philippe Msellati
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.